282
Participants
Start Date
December 31, 2003
Primary Completion Date
December 31, 2006
Study Completion Date
December 31, 2006
Entecavir
Tablet, P.O. 0.5, 1 mg, once daily
Local Institution, Aichi-Gun
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Chiba
Local Institution, Kurume
Local Institution, Takamatsu
Local Institution, Kyoto
Local Institution, Sendai
Local Institution, Nagasaki
Local Institution, Niigata
Local Institution, Osaka
Local Institution, Suita-Shi
Local Institution, Onsen-Gun
Local Institution, Fukuoka
Local Institution, Gifu
Local Institution, Ogaki-Shi
Local Institution, Fukuyama-Shi
Local Institution, Hiroshima
Local Institution, Hiroshima
Local Institution, Asahikawa-Shi
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Akashi-Shi
Local Institution, Morioka
Local Institution, Mitoyo-Gun
Local Institution, Kumamoto
Local Institution, Miyazaki-Gun
Local Institution, Matsumoto
Local Institution, Omura-Shi
Local Institution, Oita-Gun
Local Institution, Kurashiki-Shi
Local Institution, Okayama
Local Institution, Okayama
Local Institution, Okayama
Local Institution, Tsuyama-Shi
Local Institution, Kawachinagano-Shi
Local Institution, Osaka
Local Institution, Sakai-Shi
Local Institution, Iruma-Gun
Local Institution, Minato-Ku
Local Institution, Musashino-Shi
Local Institution, Shinjuku-Ku
Local Institution, Shinjuku-Ku
Local Institution, Shinjuku-Ku
Local Institution, Tokyo
Local Institution, Ube-Shi
Local Institution, Nakakoma-Gun
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY